PA
DAWN

Parallel Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Parallel Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-142
Closed -$923 – 3583
2025
Q2 		$923 Buy
142
+138
+3,450% +$949 ﹤0.01% 3209
2025
Q1 		$32 Hold
4
– – ﹤0.01% 3477
2024
Q4 		$51 Buy
+4
New +$56 ﹤0.01% 3480

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Parallel Advisors's DAWN Position: Q3 2025 in Review

Parallel Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q3 2025, closing a stake of 142 shares — an estimated $923 sold.

Parallel Advisors first reported a position in DAWN in Q4 2024 and held it in 3 quarters. The position peaked at $923 in Q2 2025. 172 funds tracked by Wall St. Rank hold DAWN as of Q3 2025.

  • Parallel Advisors reported no remaining Day One Biopharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Parallel Advisors sold 142 Day One Biopharmaceuticals shares in Q3 2025, an estimated $923.
  • Parallel Advisors first reported a position in Day One Biopharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Parallel Advisors's Day One Biopharmaceuticals position peaked at $923 in Q2 2025.
  • 172 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2025.

Based on Parallel Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.